Corcept Therapeutics
CORT
225 hedge funds and large institutions have $2.02B invested in Corcept Therapeutics in 2022 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 75 increasing their positions, 90 reducing their positions, and 21 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
19% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 21
10% more capital invested
Capital invested by funds: $1.84B → $2.02B (+$182M)
2.23% more ownership
Funds ownership: 76.8% → 79.03% (+2.2%)
1% less funds holding
Funds holding: 228 → 225 (-3)
17% less repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 90
27% less call options, than puts
Call options by funds: $4.45M | Put options by funds: $6.06M
Top Buyers
| 1 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$55M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$17.4M |
| 3 |
PA
Parallel Advisors
San Francisco,
California
|
+$16.9M |
| 4 |
D.E. Shaw & Co
New York
|
+$10.7M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$5.54M |
Top Sellers
| 1 |
Millennium Management
New York
|
-$25.1M |
| 2 |
SG Americas Securities
New York
|
-$14.8M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$12.3M |
| 4 |
Man Group
London,
United Kingdom
|
-$9.71M |
| 5 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$4.97M |
CORT Hedge Fund Activity: Q2 2022 in Review
225 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q2 2022, worth a combined $2.02B — up 9.9% from $1.84B a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new CORT positions and 21 closed out — a net gain of 4 holders — while 75 added to existing stakes and 90 trimmed.
The largest buyer was Novo Holdings A/S, opening a new position worth an estimated $55M. The largest seller was Millennium Management, cutting an estimated $25.1M.
- 225 institutional investors held Corcept Therapeutics (CORT) as of Q2 2022, down from 228 in Q1 2022.
- Funds reported $2.02B of Corcept Therapeutics stock for Q2 2022, up 9.9% quarter-over-quarter.
- 25 funds opened new Corcept Therapeutics positions in Q2 2022 and 21 closed out, a net change of +4 holders.
- The largest Corcept Therapeutics buyer in Q2 2022 was Novo Holdings A/S, an estimated $55M added.
- The largest Corcept Therapeutics seller in Q2 2022 was Millennium Management, an estimated $25.1M sold.
Based on aggregated 13F filings for Q2 2022.